The pharmaceutical industry has become one of the world’s most competitive and fast moving, with countless new therapies emerging every day. As a result of continuing innovation, regulation in the sector has toughened up enormously, and leaders are being pushed to keep on top of it all. One CEO who has impressed the international community with his excellent organisational skills is Gianclaudio Broggi of Mega Pharma, a company that produces innovative therapeutic solutions. Broggi has been on the firm’s board of directors for 14 years and became CEO in 2015, having previously been Mega Pharma’s Corporate CFO.

One of Broggi’s most impressive skills is his ability to monitor trends both in the pharmaceutical sector and in the Latin American market generally. He has remained particularly aware of the region’s slowdown within the pharma industry, a fact that is mostly due to lower commodity prices and a more competitive and regulated legal framework. In response to this, many companies have reined in their ambitions, but Broggi has done the opposite: through creating an aggressive 2020 plan, he aims to double Mega Pharma’s turnover and capture a greater market share.

Perhaps the most significant step Broggi has taken towards his goal was to develop a cutting-edge Mega Pharma R&D centre in Uruguay, where the company’s employees will be able to collaborate with some of the world’s greatest medical experts and physicians. The firm is constantly on the lookout for new opportunities, having recently acquired the oldest pharmaceutical organisation in Brazil, which will help Mega Pharma capture the market there.

Speaking about Mega Pharma, Broggi has stated the importance of investing in its people in order to guarantee that clients’ needs are met. He believes that high ethical and accountable standards, as well as research and innovation, create the perfect conditions in which to achieve success.